NCT02528409View on ClinicalTrials.gov

Vortioxetine for Binge Eating Disorder

PHASE2CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 1, 2018

Conditions

Binge Eating Disorder

Interventions

DRUG

Vortioxetine

Medication currently approved for major depression.

DRUG

Placebo

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Takeda

INDUSTRY

lead

University of Chicago

OTHER